8-K: ESSA Pharma Amends XenoTherapeutics Deal, Lowers Cash Payout

ESSA Pharma Inc. announced an amendment to its Business Combination Agreement with XenoTherapeutics, reducing the expected cash distribution to shareholders at closing and introducing contingent value rights.

Summary

• ESSA Pharma Inc. has entered into an Amendment Agreement to its Business Combination Agreement with XenoTherapeutics, Inc. and XOMA Royalty Corporation.
• Shareholders are now expected to receive approximately US$0.12 cash per Common Share at closing, exclusive of future non-transferable contingent value right (CVR) payments and the approximately US$1.69 of cash previously distributed.
• The original estimated aggregate distribution was approximately US$1.91 per Common Share (before the US$1.69 initial distribution).
• Shareholders will also receive one CVR for each Common Share, representing the right to receive up to approximately US$0.14 per CVR, payable within specified periods following the close of the Transaction.
• The potential CVR payment of US$0.14 per Common Share represents up to US$6.7 million in the aggregate, contingent on the outcome of certain liabilities.
• These changes are being made due to potential liabilities, associated expenses, and the latest estimates of the Company's expected cash balance at closing.
• The special meeting of shareholders, optionholders, and warrantholders has been further adjourned from September 29, 2025, to October 3, 2025, at 2:00 p.m. (Pacific Time) via webcast.

Sentiment

Score: 3

Explanation: The significant reduction in guaranteed cash payout and the introduction of contingent value rights for a portion of the consideration introduce substantial uncertainty and reduce immediate shareholder value, despite the transaction still moving forward.

Positives

• The business combination transaction with XenoTherapeutics and XOMA Royalty Corporation is proceeding, albeit with amended terms, indicating continued progress towards a resolution for ESSA Pharma.
• Shareholders will receive Contingent Value Rights (CVRs) offering potential future payments of up to US$0.14 per CVR, totaling up to US$6.7 million, depending on the resolution of specified contingent liabilities.

Negatives

• The expected cash distribution to shareholders at closing has been significantly reduced to approximately US$0.12 per Common Share, a substantial decrease from the originally estimated US$1.91 aggregate distribution (before the US$1.69 initial distribution).
• A portion of the consideration is now contingent and tied to the outcome of specific liabilities, introducing uncertainty and risk regarding the final value shareholders will receive.
• The reduction in cash and introduction of CVRs are attributed to potential liabilities, associated expenses, and lower-than-expected cash balance at closing, indicating a less favorable financial position for the company.

Risks

• The completion of the Transaction on anticipated terms and timing, including obtaining required securityholder, regulatory, and court approvals, and the satisfaction of other conditions.
• The potential for the date of the Special Meeting to change again.
• Potential litigation relating to the Transaction that could be instituted by or against the Company, Xeno, XOMA Royalty, or their respective directors or officers, including the effects of any outcomes related thereto.
• Potential exposure or liability relating to the due bill communication matter that occurred on August 25, 2025.
• The risk that disruptions from the Transaction will harm the Company's business, including current plans and operations.
• The ability of the Company to retain and hire key personnel.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction.
• Continued availability of capital and financing and rating agency actions.
• Legislative, regulatory, and economic developments affecting the Company's business.
• The accuracy of the Company's financial projections.
• General business, market, and economic conditions.
• Certain restrictions during the pendency of the Transaction that may impact the Company's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism, pandemics, outbreaks of war or hostilities.
• Significant transaction costs associated with the Transaction.
• The possibility that the Transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events.
• Competitive responses to the Transaction.
• Risks and uncertainties pertaining to the Company's business, including those set forth in the Company's Annual Report on Form 10-K dated December 17, 2024, and the definitive proxy statement filed August 11, 2025.

Future Outlook

The company expects the business combination transaction to close, subject to securityholder, regulatory, and court approvals. The Special Meeting has been adjourned to October 3, 2025, to allow shareholders to consider the amended agreement. The potential for CVR payments is contingent on the resolution of specified liabilities, with no assurance that holders will receive any payments.

Management Comments

• ESSA and Xeno are making this change in light of potential liabilities, associated expenses, and the latest estimates of the Company's expected cash balance at closing.
• The additional adjournment will allow time for shareholders to consider and approve the Amended Agreement.
• Shareholders who have already voted on the transaction and do not wish to change their vote do not need to take any further action.

Industry Context

The amendment to the business combination agreement, particularly the reduction in upfront cash and the introduction of contingent value rights (CVRs), reflects a trend in biotechnology M&A where deal structures are increasingly incorporating mechanisms to manage risk associated with uncertain future liabilities or asset performance. This approach allows for a transaction to proceed while deferring a portion of the consideration based on future events, which can be attractive in a volatile market or when dealing with companies with complex contingent obligations.

Legal Proceedings

• Potential litigation relating to the Transaction that could be instituted by or against the Company, Xeno, XOMA Royalty, or their respective directors or officers.
• Potential exposure or liability relating to the due bill communication matter that occurred on August 25, 2025.
• The CVR agreement defines 'Company Litigation' and 'Potential Contingent Claim Liability' which are ongoing or potential legal matters that could impact CVR payments.

Stakeholder Impact

• Shareholders: Face a reduced immediate cash payout and the introduction of contingent value rights (CVRs) with uncertain future payments, requiring a re-evaluation of the transaction's value.
• Management/Employees: May experience disruptions from the transaction, affecting current plans and operations, and potential challenges in retaining and hiring key personnel.
• XenoTherapeutics/XOMA Royalty: The amendment reflects adjustments to the deal structure to account for ESSA's potential liabilities and cash balance, impacting their acquisition terms and financial commitments.

Next Steps

• ESSA will file supplemental proxy materials reflecting the Amendment in due course.
• The special meeting of shareholders, optionholders, and warrantholders will reconvene on October 3, 2025.
• ESSA intends to apply to the Supreme Court of British Columbia to amend the interim order for a new meeting date, dissent deadline, and court hearing date.
• The new deadline to deliver notices of dissent is October 1, 2025.
• The new Court hearing date for approval of the Arrangement is October 7, 2025.
• The deadline of October 3, 2025, is set for responses from persons intending to attend the October 7th hearing.

Key Dates

Recommendation

The significant reduction in the guaranteed cash component of the acquisition consideration, coupled with the introduction of contingent value rights (CVRs) that are non-transferable and dependent on the resolution of uncertain liabilities, substantially diminishes the immediate and certain value for shareholders. This shift from a higher fixed cash payout to a lower fixed cash plus a speculative contingent payment increases risk and uncertainty, making the revised terms less attractive. Seasoned investors would likely view this as a deterioration of the deal's value proposition, prompting a recommendation to sell.

Keywords

Business Combination, Amendment Agreement, Contingent Value Rights, CVR, XenoTherapeutics, XOMA Royalty, ESSA Pharma, Merger, Acquisition, Biotechnology, Prostate Cancer, SEC Filing, 8-K